Claims
- 1. A method for delivering an antineoplastic agent to a normal or non-neoplastic solid tissue which comprises:injecting directly into said solid tissue a therapeutically effective volume of a solution comprising a pharmaceutically acceptable water miscible organic solvent and a therapeutically effective amount of said antineoplastic agent; said solution having a partition coefficient of at least about 0.1; and said antineoplastic agent being stable and bioavailable in said solution; wherein the normal or non-neoplastic solid tissue is effectively perfused by the antineoplastic agent.
- 2. The method of claim 1 which comprises injecting an amount of said solution sufficient to treat a pre-selected abnormal tissue component in said non-neoplastic tissue.
- 3. The method of claim 1 which comprises injecting an amount of said solution sufficient to treat a pre-selected foreign element in said non-neoplastic tissue.
- 4. The method of claim 1 which comprises injecting an amount of said solution sufficient to treat in said non-neoplastic tissue at least two treatment targets selected from a pre-selected normal tissue component, a preselected abnormal tissue component and a preselected foreign element.
- 5. The method of claim 1 which comprises injecting a volume of said solution smaller than a volume of the tissue treated.
- 6. The method of claim 1 wherein said antineoplastic agent comprises BCNU.
- 7. The method of claim 1 wherein said solvent comprises ethanol.
- 8. The method of claim 7 wherein said ethanol comprises absolute ethanol.
- 9. The method of claim 1 wherein the antineoplastic agent comprises a pharmaceutical agent.
- 10. The method of claim 1 wherein the antineoplastic agent comprises a biological agent.
- 11. The method of claim 1 wherein the antineoplastic agent comprises an angiogenic agent.
- 12. A method for delivering an antineoplastic agent to a non-neoplastic solid tissue which comprises:injecting into an area adjacent to said solid non-neoplastic tissue a therapeutically effective volume of a solution comprising a pharmaceutically acceptable water miscible organic solvent and a therapeutically effective amount of said antineoplastic agent; said solution having a partition coefficient of at least about 0.1; and said antineoplastic agent being stable and bioavailable in said solution; wherein the non-neoplastic solid tissue is effectively perfused by the antineoplastic agent.
- 13. The method of claim 12 wherein said area is one of a normal tissue area, a neoplastic tissue area and a cavity.
- 14. The method of claim 13 wherein said cavity is one of a naturally occurring boy cavity and a cavity formed by surgical resection.
- 15. The method of claim 12 which comprises injecting an amount of said solution sufficient to treat a pre-selected abnormal tissue component in said non-neoplastic tissue.
- 16. The method of claim 12 which comprises injecting an amount of said solution sufficient to treat a pre-selected foreign element in said non-neoplastic tissue.
- 17. The method of claim 12 which comprises injecting an amount of said solution sufficient to treat in said non-neoplastic tissue at least two treatment targets selected from a pre-selected normal tissue component, a preselected abnormal tissue component and a preselected foreign element.
- 18. The method of claim 12 which comprises injecting a volume of said solution smaller than a volume of the tissue treated.
- 19. The method of claim 12 wherein said antineoplastic agent comprises BCNU.
- 20. The method of claim 12 wherein said solvent comprises ethanol.
- 21. The method of claim 20 wherein said ethanol comprises absolute ethanol.
- 22. The method of claim 12 wherein the antineoplastic agent comprises a pharmaceutical agent.
- 23. The method of claim 12 wherein the antineoplastic agent comprises a biological agent.
- 24. The method of claim 12 wherein the antineoplastic agent comprises an angiogenic agent.
- 25. A method for delivering an antineoplastic agent to a normal or non-neoplastic solid tissue which comprises:preparing a therapeutically effective volume of a solution consisting essentially of a pharmaceutically acceptable water miscible organic solvent and a therapeutically effective amount of said antineoplastic agent, said solution having a partition coefficient of at least about 0.1, and said antineoplastic agent being stable and bioavailable in said solution; and injecting said volume of said solution directly into said solid tissue; wherein the normal or non-neoplastic solid tissue is effectively perfused by the antineoplastic agent.
Parent Case Info
The present application is a divisional application of U.S. application Ser. No. 09/224,599, filed Dec. 31, 1998, which claims the benefit of priority of U.S. Provisional Application No. 60/070,175, filed Dec. 31, 1997. The disclosure of each of the foregoing applications is hereby incorporated herein by reference, in its entirety.
US Referenced Citations (9)
Number |
Name |
Date |
Kind |
3957996 |
Adams et al. |
May 1976 |
A |
3966934 |
Adams et al. |
Jun 1976 |
A |
4536387 |
Sakamoto et al. |
Aug 1985 |
A |
5023271 |
Vigne et al. |
Jun 1991 |
A |
5051257 |
Pietronigro |
Sep 1991 |
A |
5162115 |
Pietronigro et al. |
Nov 1992 |
A |
5610173 |
Schwartz et al. |
Mar 1997 |
A |
5789244 |
Heidrun et al. |
Aug 1998 |
A |
5851527 |
Hansen |
Dec 1998 |
A |
Non-Patent Literature Citations (1)
Entry |
American Society of Hospital Pharmacists (ASHP), Drug Information Manual, Listing for Carmustine, section 10:00, 1994 edition. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/070175 |
Dec 1997 |
US |